Repotrectinib

Brand names: Augtyro · Active ingredient: Repotrectinib

In short: AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) . AUGTYRO is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that: •have a neurotrophic tyrosine recep

Forms & strengthsCapsules: 40 mg, white, opaque, immediate release, Size 0, hard shell capsule, filled with white to off-white powder which may appear as a plug, imprinted with “REP 40” in blue text on the cap. …
LabelE.R. Squibb & Sons, L.L.C.
Label updatedAug 11, 2026

What is Repotrectinib used for?

AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) .

AUGTYRO is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:

•have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion ,

•are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and

•have progressed following treatment or have no satisfactory alternative therapy.

This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Repotrectinib dosage

NSCLC

Select patients for the treatment of locally advanced or metastatic NSCLC with AUGTYRO based on the presence of ROS1 rearrangement(s) in tumor specimens . An FDA-approved test to detect ROS1 rearrangements for selecting patients for treatment with AUGTYRO is not currently available.

Solid Tumors

Select patients for the treatment of solid tumors with AUGTYRO based on the presence of NTRK1/2/3 rearrangements in tumor specimens . An FDA-approved test to detect NTRK1/2/3 rearrangements for selecting patients for treatment with AUGTYRO is not currently available.

•

In patients with secretory breast cancer or mammary analogue secretory cancer, consider treatment without confirmation of NTRK rearrangements in tumor specimens.

Prior to initiating AUGTYRO, discontinue strong and moderate CYP3A inhibitors for 3 to 5 elimination half-lives of the CYP3A inhibitor .

Prior to initiation of AUGTYRO, evaluate:

•liver function tests including bilirubin

•uric acid level

The recommended dosage of AUGTYRO for adult and pediatric patients 12 years of age and older is 160 mg taken orally once daily with or without food for 14 days, then increase to 160 mg twice daily and continue until disease progression or unacceptable toxicity.

The recommended dosage reductions of AUGTYRO for the management of adverse reactions are provided in Table 1.

Dose | Dose Reduction

First | Second

160 mg Once Daily | 120 mg Once Daily | 80 mg Once Daily

160 mg Twice Daily | 120 mg Twice Daily | 80 mg Twice Daily

Recommended dosage modifications of AUGTYRO for the management of adverse reactions are provided in Table 2.

*Graded per Common Terminology Criteria for Adverse Events v4.03

Adverse Reaction | Severity* | Dosage Modification

Central Nervous System Effects

| Intolerable

Grade 2 | •Withhold AUGTYRO until ≤Grade 1 or baseline.

•Resume at same or reduced dose, as clinically appropriate.

Grade 3 | •Withhold AUGTYRO until ≤Grade 1 or baseline.

•Resume at reduced dose.

Grade 4 | •Permanently discontinue AUGTYRO.

Interstitial Lung Disease (ILD)/Pneumonitis

| Any Grade | •Withhold AUGTYRO if ILD/pneumonitis is suspected.

•Permanently discontinue if ILD/pneumonitis is confirmed.

Hepatotoxicity

| Grade 3 | •Withhold AUGTYRO until ≤Grade 1 or baseline.

•Resume at same dose if resolution occurs within 4 weeks.

•Resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.

Grade 4 | •Withhold AUGTYRO until ≤Grade 1 or baseline.

•Resume at reduced dose.

•Permanently discontinue if adverse reaction does not resolve within 4 weeks.

•Permanently discontinue for recurrent Grade 4 events.

ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis) | •Permanently discontinue AUGTYRO. …

How to take Repotrectinib — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Patient Information).

Central Nervous System (CNS) Effects

•Advise patients to inform their healthcare provider if they experience new or worsening CNS symptoms. Instruct patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions .

Interstitial Lung Disease (ILD)/Pneumonitis

•Advise patients to inform their healthcare provider if they experience new or worsening pulmonary symptoms indicative of ILD/pneumonitis .

Hepatotoxicity

•Advise patients of the need for laboratory tests to monitor liver function and to immediately report symptoms of hepatotoxicity .

Myalgia with Creatine Phosphokinase Elevation

•Advise patients to inform their healthcare provider if they experience muscle pain .

Hyperuricemia

•Advise patients to inform their healthcare provider if they experience signs or symptoms associated with hyperuricemia .

Skeletal Fractures

•Inform patients that bone fractures have occurred in patients taking AUGTYRO and advise patients to report symptoms to their healthcare provider . …

Warnings & precautions

Do not take this medicine if: None.

AUGTYRO can cause central nervous system adverse reactions.

Among the 426 patients who received AUGTYRO in Study TRIDENT-1, a broad spectrum of central nervous system (CNS) adverse reactions including dizziness, ataxia, and cognitive disorders occurred in 77% of patients, with Grade 3 or 4 events occurring in 4.5% of patients.

Dizziness, including vertigo, occurred in 65% of patients; Grade 3 dizziness occurred in 2.8% of patients. The median time to onset was 7 days (1 day to 1.4 years). Dose interruption was required in 9% of patients, and 11% required dose reduction of AUGTYRO due to dizziness.

Ataxia, including gait disturbance and balance disorder, occurred in 28% of patients; Grade 3 ataxia occurred in 0.5% of patients. The median time to onset was 15 days (1 day to 1.4 years). Dose interruption was required in 5% of patients, 8% required dose reduction, and one patient (0.2%) permanently discontinued AUGTYRO due to ataxia.

Cognitive impairment, including memory impairment and disturbance in attention, occurred in 25% of patients. Cognitive impairment included memory impairment (15%), disturbance in attention (12%), and confusional state (2%); Grade 3 cognitive impairment occurred in 0.9% of patients. The median time to onset of cognitive disorders was 37 days (1 day to 1.4 years). Dose interruption was required in 2% of patients, 2.1% required dose reduction, and 0.5% patients permanently discontinued AUGTYRO due to cognitive adverse reactions.

Mood disorders occurred in 6% of patients. Mood disorders occurring in > 1% of patients included anxiety (2.6%); Grade 4 mood disorders (mania) occurred in 0.2% of patients. Dose interruption was required in 0.2% of patients and 0.2% of patients required a dose reduction due to mood disorders.

Sleep disorders including insomnia and hypersomnia occurred in 18% of patients. …

Repotrectinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Central Nervous System Adverse Reactions

•Interstitial Lung Disease (ILD)/Pneumonitis

•Hepatotoxicity

•Myalgia with Creatine Phosphokinase Elevation

•Hyperuricemia

•Skeletal Fractures

•Embryo-Fetal Toxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates reported in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in WARNINGS AND PRECAUTIONS and below reflects exposure to AUGTYRO in 426 patients with ROS1-positive NSCLC (n=320), NTRK1/2/3-positive solid tumors (n=104), or other solid tumors (n=2) in TRIDENT-1. Patients received AUGTYRO at a dose of 160 mg orally once daily for the first 14 days, then increased to 160 mg orally twice daily until disease progression or unacceptable toxicity . Eligible patients had an ECOG status of ≤1. Patients with a history of ILD, drug-related pneumonitis, significant, uncontrolled, active cardiovascular disease, or prolonged QTc interval were excluded from enrollment in this trial. Forty-eight percent of patients were exposed to AUGTYRO for at least 6 months, and 28% were exposed for greater than 1 year. …

Drug interactions

Strong and Moderate CYP3A Inhibitors

Avoid concomitant use with strong or moderate CYP3A inhibitors. Concomitant use of AUGTYRO with a strong or a moderate CYP3A inhibitor may increase repotrectinib exposure, which may increase the incidence and severity of adverse reactions of AUGTYRO. Discontinue CYP3A inhibitors for 3 to 5 elimination half-lives of the CYP3A inhibitor prior to initiating AUGTYRO .

P-gp Inhibitors

Avoid concomitant use with P-gp inhibitors. Concomitant use of AUGTYRO with a P-gp inhibitor may increase repotrectinib exposure, which may increase the incidence and severity of adverse reactions of AUGTYRO .

Strong and Moderate CYP3A Inducers

Avoid concomitant use with strong or moderate CYP3A inducers. Concomitant use of AUGTYRO with a strong or moderate CYP3A inducer may decrease repotrectinib plasma concentrations, which may decrease efficacy of AUGTYRO .

Certain CYP3A4 Substrates

Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates, where minimal concentration changes can cause reduced efficacy. If concomitant use is unavoidable, increase the CYP3A4 substrate dosage in accordance with approved product labeling.

Repotrectinib is a CYP3A4 inducer. …

About this medicine

Repotrectinib is a kinase inhibitor. The molecular formula for repotrectinib is C18H18FN5O2 and the molecular weight is 355.37 Daltons. The chemical name is (3R,11S)-6-Fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4,6,8,15(22),16,19-heptaen-14-one. The chemical structure of repotrectinib is as follows:

Repotrectinib is a white to off-white powder.

AUGTYRO (repotrectinib) capsules for oral use are supplied as printed hard shell capsules containing 40 mg of repotrectinib. Inactive ingredients are microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, and colloidal silicon dioxide.

The white opaque capsule shell contains gelatin and titanium dioxide. The printing ink contains shellac and FD & C blue #2 aluminum lake.

AUGTYRO (repotrectinib) capsules for oral use are supplied as printed hard shell capsules containing 160 mg of repotrectinib. Inactive ingredients are microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fb526827-40ba-4462-94cf-179ae3b0cb8a. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate